13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001974915
Total reported value
$4.3B
$4.3B
81 檔
11.3%
At the close of Q3 2025, Vestal Point Capital, LP disclosed equity holdings valued at approximately $4.3B, spread across 81 reported holdings.
In Q3 2025, Vestal Point Capital, LP displayed an active expansion posture, initiating 36 new positions and adding to 22 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | Stock-Other | 5.39% | -2.40% | EXIT | |
| 2 | ACLXGBX | Arcellx Inc | Stock-Other | 4.63% | — | -54.55% | |
| 3 | NUVL | Nuvalent Inc-a | Stock-Other | 4.30% | -1.38% | EXIT | |
| 4 | ABVX | Abivax Sa-adr | Stock-Other | 3.83% | +2.65% | — | |
| 5 | ALC | Alcon Inc. | Stock-Healthcare | 3.70% | -0.91% | +109.52% | |
| 6 | BCAX | Bicara Therapeutics Inc | Stock-Other | 3.64% | +0.62% | +2.00% | |
| 7 | AM6 | Amicus Therapeutics Inc | Stock-Other | 3.47% | — | -18.07% | |
| 8 | GMED | Globus Medical Inc - A | Stock-Healthcare | 3.23% | +0.10% | +150.00% | |
| 9 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 3.18% | — | +115.00% | |
| 10 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 2.98% | — | -58.33% | |
| 11 | BDX | Becton Dickinson And Co | Stock-Healthcare | 2.75% | — | +1200.00% | |
| 12 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.52% | -1.82% | EXIT | |
| 13 | ✓ | Immatics NV | Stock-Other | 2.44% | -0.24% | +1.60% | |
| 14 | RGEN | Repligen CORP | Stock-Healthcare | 2.41% | -1.77% | — | |
| 15 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.10% | — | -63.13% | |
| 16 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.03% | +2.41% | +66.00% | |
| 17 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.99% | -0.05% | -45.00% | |
| 18 | DXCM | Dexcom Inc | Stock-Healthcare | 1.98% | — | — | |
| 19 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.80% | -0.55% | EXIT | |
| 20 | BIIB | Biogen Inc | Stock-Healthcare | 1.74% | — | — | |
| 21 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.73% | — | -20.00% | |
| 22 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.63% | — | +9.60% | |
| 23 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.59% | -0.28% | +281.44% | |
| 24 | TYRA | Tyra Biosciences Inc | Stock-Other | 1.53% | -0.06% | EXIT | |
| 25 | ABT | Abbott Laboratories | Stock-Healthcare | 1.51% | +2.97% | NEW | |
| 26 | IRON | Disc Medicine Inc | Stock-Other | 1.49% | +1.40% | +257.14% | |
| 27 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.45% | +1.74% | +73.75% | |
| 28 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.41% | — | -50.00% | |
| 29 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.41% | -1.09% | EXIT | |
| 30 | ZYME | Zymeworks Inc | Stock-Other | 1.36% | — | +53.48% | |
| 31 | DHR | Danaher CORP | Stock-Healthcare | 1.34% | — | +200.00% | |
| 32 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.33% | -4.49% | -47.50% | |
| 33 | RAPP | Rapport Therapeutics Inc | Stock-Other | 1.27% | -0.55% | — | |
| 34 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.07% | +1.18% | +364.00% | |
| 35 | GERN | Geron CORP | Stock-Other | 1.07% | -0.11% | EXIT | |
| 36 | BLTE | Belite Bio Inc - Adr | Stock-Other | 1.04% | — | — | |
| 37 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.02% | — | — | |
| 38 | VERA | Vera Therapeutics Inc | Stock-Other | 1.00% | -1.54% | EXIT | |
| 39 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.97% | -0.25% | +0.68% | |
| 40 | BDTX | Black Diamond Therapeutics I | Stock-Other | 0.95% | — | -0.89% | |
| 41 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.85% | — | -10.83% | |
| 42 | SLDB | Solid Biosciences Inc | Stock-Other | 0.83% | -0.51% | +97.67% | |
| 43 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.82% | — | — | |
| 44 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.81% | +0.84% | +83.33% | |
| 45 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.76% | -2.59% | EXIT | |
| 46 | SVRA | Savara Inc | Stock-Other | 0.65% | -0.01% | -63.55% | |
| 47 | BRKR | Bruker CORP | Stock-Healthcare | 0.65% | — | -12.00% | |
| 48 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.63% | -0.28% | — | |
| 49 | QURE | uniQure N.V. | Stock-Other | 0.59% | +0.85% | -93.92% | |
| 50 | BBNX | Beta Bionics Inc | Stock-Other | 0.54% | -0.03% | +9.09% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | +3.7% | +200.00% | Add |
| 2 | GMED | Globus Medical Inc - A | +2.2% | +150.00% | Add |
| 3 | CLDX | Celldex Therapeutics Inc | +1.2% | -31.14% | Add |
| 4 | BCAX | Bicara Therapeutics Inc | +1.1% | +2.00% | Add |
| 5 | AM6 | Amicus Therapeutics Inc | +1% | -18.07% | Add |
| 6 | CDTX | Cidara Therapeutics Inc | +1% | -20.00% | Trim |
| 7 | ZYME | Zymeworks Inc | +0.9% | +53.48% | Add |
| 8 | LXEO | Lexeo Therapeutics Inc | +0.7% | +0.68% | Add |
| 9 | NRIX | Nurix Therapeutics Inc | +0.5% | +73.75% | Add |
| 10 | SLDB | Solid Biosciences Inc | +0.4% | +97.67% | Add |
| 11 | BDTX | Black Diamond Therapeutics I | +0.3% | -0.89% | Trim |
| 12 | DYN | Dyne Therapeutics Inc | +0.3% | +281.44% | Add |
| 13 | VTYXUSD | Ventyx Biosciences Inc | +0.1% | +2.50% | Add |
| 14 | ✓ | Immatics NV | +0.1% | +1.60% | Trim |
| 15 | ALEC | Alector Inc | +0.1% | +0.31% | Add |
| 16 | CATBUSD | Astria Therapeutics Inc | 0% | +9.60% | Add |
| 17 | ANRO | Alto Neuroscience Inc | 0% | — | Add |
| 18 | VYGR | Voyager Therapeutics Inc | 0% | — | Add |
| 19 | FATE | Fate Therapeutics Inc | — | — | Trim |
| 20 | TENX | Tenax Therapeutics Inc | — | — | Unchanged |
| 21 | APLT | Applied Therapeutics Inc | 0% | +23.91% | Add |
| 22 | ✓ | Engene Holdings Inc | 0% | — | Unchanged |
| 23 | MGNX | Macrogenics Inc | 0% | — | Unchanged |
| 24 | STRO | Sutro Biopharma, Inc. | 0% | — | Unchanged |
| 25 | TRAW | Traws Pharma Inc | 0% | +0.13% | Trim |
| 26 | DNTH | Dianthus Therapeutics Inc | -0.1% | -63.13% | Trim |
| 27 | OKUR | Onkure Therapeutics Inc-a | -0.1% | — | Unchanged |
| 28 | BRKR | Bruker CORP | -0.2% | -12.00% | Add |
| 29 | RARE | Ultragenyx Pharmaceutical In | -0.3% | — | Add |
| 30 | TYRA | Tyra Biosciences Inc | -0.4% | -8.66% | Trim |
| 31 | SRRK | Scholar Rock Holding CORP | -0.5% | — | Add |
| 32 | DHR | Danaher CORP | -0.5% | +200.00% | Add |
| 33 | DAWNGBX | Day One Biopharmaceuticals I | -0.6% | -10.83% | Add |
| 34 | ✓ | Nyxoah S A | -0.9% | -21.01% | Trim |
| 35 | ✓ | Establishment Labs Holdings In | -1.1% | — | Trim |
| 36 | XENE | Xenon Pharmaceuticals Inc | -1.1% | -45.00% | Trim |
| 37 | NUVL | Nuvalent Inc-a | -1.1% | +2.33% | Add |
| 38 | GERN | Geron CORP | -1.4% | -27.55% | Trim |
| 39 | SVRA | Savara Inc | -1.5% | -63.55% | Trim |
| 40 | CRNX | Crinetics Pharmaceuticals In | -2.2% | -50.00% | Trim |
| 41 | QURE | uniQure N.V. | -3% | -93.92% | Trim |
| 42 | VERA | Vera Therapeutics Inc | -3.3% | -75.48% | Trim |
| 43 | 4XC1 | Kalvista Pharmaceuticals Inc | -3.5% | -83.96% | Trim |
| 44 | CYTK | Cytokinetics Inc | -5.6% | -75.63% | Trim |
| 45 | ACLXGBX | Arcellx Inc | -6.6% | -54.55% | Trim |
| 46 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 47 | INSM | Insmed Inc | — | EXIT | Sold out |
| 48 | ALC | Alcon Inc. | — | NEW | New buy |
| 49 | IONS | Ionis Pharmaceuticals Inc | — | NEW | New buy |
| 50 | JAZZ | Jazz Pharmaceuticals plc | — | NEW | New buy |
According to official SEC Form 13F filings, Vestal Point Capital, LP reported a total U.S. public equity portfolio value of $4.3B across 81 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ASND, ACLXGBX, NUVL) accounted for 11.3% of total reported equity market value during Q3 2025.
Top New Position Initiated
ABVX
市值: $84.9M
Top Position Liquidated / Trimmed
INSM
前期市值: $82.0M
During Q3 2025, Vestal Point Capital, LP's top holdings by market value included ASND (5.4%)、ACLXGBX (4.6%)、NUVL (4.3%). The largest single position, ASND, represented 5.4% of total portfolio value.
In Q3 2025, Vestal Point Capital, LP made 94 total portfolio adjustments, initiating 36 new buys, adding to 22 positions, trimming 18 holdings, and fully liquidating 18 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.